Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519460 | 0.88 | IGF1R (0.65) | SIRT6IGF1RMAPTALDH1A1HTT | |
| SCHEMBL519461 | 0.88 | IGF1R (0.65) | SIRT6IGF1RMAPTALDH1A1HTT | |
| SCHEMBL519813 | 0.88 | IGF1R (0.65) | SIRT6IGF1RMAPTALDH1A1HTT | |
| SCHEMBL1046934 | 0.85 | HTR1A (0.65) | SIRT6IGF1RMAPTPOLBLMNA | |
| SCHEMBL7768027 | 0.85 | IGF1R (0.55) | SIRT6IGF1RMAPTALDH1A1HTT | |
| SCHEMBL3756774 | 0.85 | MAPT (0.56) | SIRT6IGF1RMAPTALDH1A1HTT | |
| SCHEMBL374222 | 0.83 | SIRT6 (0.68) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL6151230 | 0.82 | SIRT6 (0.81) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL15271381 | 0.82 | SIRT6 (0.81) | SIRT6MAPTALDH1A1POLBLMNA | |
| SCHEMBL2509037 | 0.82 | SIRT6 (0.66) | SIRT6IGF1RMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100482651-C | Diaminothiazoles | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | CN | disclosed |
| US-7105670-B2 | Intermediates useful in the preparation of diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7094896-B2 | Diaminothiazoles having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1358169-B1 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | DING QINGJIE (US) | 2004-04-29 | — | — | US | disclosed |
| CN-1487927-A | Diaminothiazoles | - | 2004-04-07 | — | — | CN | disclosed |
| EP-1358169-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | SIRT6 732/4885IGF1R 825/4885MAPT 3064/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | SIRT6 732/4885IGF1R 825/4885MAPT 3064/4885 |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | CDK4, CDK2, CDKL4 | SIRT6 612/4885IGF1R 533/4885MAPT 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.